CIK 0001678660
- Non-accelerated filer
- Smaller reporting company
Prelude Therapeutics Inc
Sign in to watch- Ticker
- PRLD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 811384762
- Phone
- +1 302-467-1280
- Business address
- 175 INNOVATION BOULEVARD, WILMINGTON, DE, 19805
- Former names
- Prelude Therapeutics Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-09-29 | BAKER BROS. ADVISORS LP Director | Conversion · Series C Convertible Preferred Stock | −382,884 | 0 | ||
| 2020-09-29 | BAKER BROS. ADVISORS LP Director | Conversion · Non-Voting Common Stock | +382,884 | 5,058,149 | ||
| 2020-09-29 | FRIEDMAN PAUL A Director | Conversion | +295,794 | 347,522 | ||
| 2020-09-29 | FRIEDMAN PAUL A Director | Conversion | +152,576 | 500,098 | ||
| 2020-09-29 | FRIEDMAN PAUL A Director | Conversion · Series A Preferred Stock | −295,794 | 0 | ||
| 2020-09-29 | FRIEDMAN PAUL A Director | Conversion · Series B Preferred Stock | −152,576 | 0 | ||
| 2020-09-29 | Bonita David P Director | Conversion | +8,332,779 | 9,250,191 | ||
| 2020-09-29 | Bonita David P Director | Conversion · Series A Preferred Stock | −3,294,743 | 0 | ||
| 2020-09-29 | Bonita David P Director | Conversion · Series A Preferred Stock | −2,196,494 | 0 | ||
| 2020-09-29 | Bonita David P Director | Conversion · Series B Preferred Stock | −4,418,186 | 0 | ||
| 2020-09-29 | Bonita David P Director | Conversion · Series B Preferred Stock | −2,945,458 | 0 | ||
| 2020-09-29 | Bonita David P Director | Conversion · Series C Preferred Stock | −619,850 | 0 | ||
| 2020-09-29 | Bonita David P Director | Conversion · Series C Preferred Stock | −413,234 | 0 | ||
| 2020-09-29 | Bonita David P Director | Conversion · Non-Voting Common Stock | +5,555,186 | 5,555,186 | ||
| 2020-09-29 | Combs Andrew EVP, Head of Chemistry | Purchase | +1,000 | $19.00 | $19K | 260,380 |
| 2020-09-29 | ORBIMED ADVISORS LLC Director | Conversion | +8,332,779 | 9,250,191 | ||
| 2020-09-29 | ORBIMED ADVISORS LLC Director | Conversion · Series A Preferred Stock | −3,294,743 | 0 | ||
| 2020-09-29 | ORBIMED ADVISORS LLC Director | Conversion · Series A Prefered Stock | −2,196,494 | 0 | ||
| 2020-09-29 | ORBIMED ADVISORS LLC Director | Conversion · Series B Preferred Stock | −4,418,186 | 0 | ||
| 2020-09-29 | ORBIMED ADVISORS LLC Director | Conversion · Series B Preferred Stock | −2,945,458 | 0 |
Page 17 of 19 · 369 trades